Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600 Mutated-Stage III/IV Melanoma”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Early research (Phase 1)Ended earlyNCT01826448
What this trial is testing

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Who this might be right for
V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Daiichi Sankyo 13
Testing effectiveness (Phase 2)Ended earlyNCT01942993
What this trial is testing

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Who this might be right for
Melanoma
Philip Friedlander 3
Very early researchLooking for participantsNCT04741997
What this trial is testing

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Who this might be right for
Melanoma Stage IIIMelanoma Stage IVBRAF V600 Mutation
H. Lee Moffitt Cancer Center and Research Institute 50
Early research (Phase 1)Active Not RecruitingNCT02721459
What this trial is testing

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Who this might be right for
MelanomaSkin Cancer
H. Lee Moffitt Cancer Center and Research Institute 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT03235245
What this trial is testing

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Who this might be right for
Unresectable Stage III MelanomaStage IV Melanoma
European Organisation for Research and Treatment of Cancer - EORTC 271
Not applicableStudy completedNCT06557291
What this trial is testing

Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma

Who this might be right for
BRAF V600 Mutated-Stage III/IV Melanoma
Novartis 38